Angioplasty, Balloon, Coronary

• 

  Subject Areas on Research

  • "Functional characteristics of a new perfusion balloon: comparison with the Flowtrack 40 in a closed chest swine". 
  • "Hugging balloons" through a single 8-French guide: salvage angioplasty with lytic therapy in the infarct vessel of a 40-year-old man. 
  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • "Sirolimus or paclitaxel drug eluting stent in left main disease: the winner is... ". 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. 
  • 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. 
  • A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. 
  • A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. 
  • A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. 
  • A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). 
  • A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. 
  • A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. 
  • A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. 
  • A preliminary study of the effects of cardiac procedures on cognitive performance. 
  • A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. 
  • A randomized comparison of the effects of gradual prolonged versus standard primary balloon inflation on early and late outcome. Results of a multicenter clinical trial. Perfusion Balloon Catheter Study Group. 
  • A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). 
  • A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. 
  • A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A risk score to predict bleeding in patients with acute coronary syndromes. 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee. 
  • ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). 
  • ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). 
  • ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures: a Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures). 
  • ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. 
  • ASCERT: the American College of Cardiology Foundation--the Society of Thoracic Surgeons Collaboration on the comparative effectiveness of revascularization strategies. 
  • Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. 
  • Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial. 
  • Accelerating ST-segment elevation myocardial infarction care: emergency medical services take center stage. 
  • Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. 
  • Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. 
  • Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Acute and long-term cost implications of coronary stenting. 
  • Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Acute profound thrombocytopenia after c7E3 Fab therapy. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adjunctive use of cutting balloon after rotational atherectomy in a young adult with probable kawasaki disease. 
  • Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Advances in antiplatelet therapy: agents in clinical development. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Advancing Procedural Success in Cardiogenic Shock Among Elderly Patients: How Can We Improve? 
  • Advancing biomarker science in the 21st century. 
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. 
  • Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial. 
  • Age, STEMI, and Cardiogenic Shock: Never Too Old for PCI? 
  • Aggressive clinical pattern of angina at restenosis following coronary angioplasty in unstable angina. 
  • Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). 
  • Aggressive therapy of acute MI in the elderly. 
  • American College of Cardiology training statement on recommendations for the structure of an optimal adult interventional cardiology training program: a report of the American College of Cardiology task force on clinical expert consensus documents. 
  • An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • An overview of the results of the EPIC trial. 
  • Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. 
  • Anatomic distribution of the culprit lesion in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: findings from the National Cardiovascular Data Registry. 
  • Angiographic follow-up after internal mammary artery graft angioplasty. 
  • Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Emory Angioplasty versus Surgery Trial Investigators. 
  • Angioscopic versus angiographic detection of thrombus during coronary interventional procedures. 
  • Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: identifying the guideposts for navigating the genetics landscape. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy and platelet function testing. Introduction. 
  • Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. 
  • Antithrombin alternatives in STEMI. 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy in patients undergoing percutaneous coronary intervention. 
  • Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 
  • Aortic counterpulsation: a review of the hemodynamic effects and indications for use. 
  • Aortic dissection after angioplasty and stenting of an aortic coarctation: detection by intravascular ultrasonography but not transesophageal echocardiography. 
  • Applying the resource-based relative value scale to the Emory angioplasty versus surgery trial. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Aspirin resistance and a single gene. 
  • Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. 
  • Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. 
  • Association of noninvasive markers of coronary artery reperfusion to assess microvascular obstruction in patients with acute myocardial infarction treated with primary angioplasty. 
  • Association of previous coronary artery bypass graft surgery with door-to-balloon time and in-hospital outcomes: a report from the National Cardiovascular Data Registry (NCDR). 
  • Autopsy validation study of the academic research consortium stent thrombosis definition. 
  • Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial. 
  • Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. 
  • Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 
  • Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry. 
  • Baseline characteristics and therapeutic goals in the New Approaches to Coronary Intervention (NACI) registry. 
  • Beneficial effects of noetic therapies on mood before percutaneous intervention for unstable coronary syndromes. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Benefits of coronary revascularization: a failure to communicate. 
  • Better functional status in American than Canadian patients with heart disease: an effect of medical care? 
  • Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 
  • Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. 
  • Bivalirudin: a review of the pharmacology and clinical application. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. 
  • Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Body mass index and effectiveness of reperfusion strategies: implications for the management of patients with ST-elevation myocardial infarction. 
  • Bridging American-Canadian health care outcome differences: is there really a gap? 
  • Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. 
  • C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. 
  • Can restenosis after coronary angioplasty be predicted from clinical variables? 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction. 
  • Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Caution in interpreting the findings from small observational studies. 
  • Cellular and molecular mechanisms of coronary artery restenosis. 
  • Certificate of Need (CON) for cardiac care: controversy over the contributions of CON. 
  • Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). 
  • Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. 
  • Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). 
  • Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. 
  • Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. 
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. 
  • Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)? 
  • Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. 
  • Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. 
  • Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. 
  • Clinical applications of antiplatelet therapy. 
  • Clinical applications of coronary sinus retroperfusion during high risk percutaneous transluminal coronary angioplasty. 
  • Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. 
  • Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. 
  • Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. 
  • Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts. 
  • Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. 
  • Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Clinical outcome after coronary artery revascularization and lung transplantation. 
  • Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. 
  • Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Clinical presentation and outcomes of drug-eluting stent-associated coronary aneurysms. 
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 
  • Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. 
  • Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. 
  • Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. 
  • Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. 
  • Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery. 
  • Combination of Goldman risk and initial cardiac troponin I for emergency department chest pain patient risk stratification. 
  • Combined TMR and mitral valve replacement via left thoracotomy. 
  • Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). 
  • Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. 
  • Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). 
  • Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008. 
  • Comparative effectiveness of revascularization strategies. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. 
  • Comparison of angioplasty with stenting in acute myocardial infarction. 
  • Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. 
  • Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). 
  • Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents. 
  • Comparison of electrocardiogram and intrathoracic electrogram signals for detection of ischemic ST segment changes during normal sinus and ventricular paced rhythms. 
  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes. 
  • Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients≥65 years with multivessel coronary artery disease. 
  • Comparison of long-term (seven year) outcomes among patients undergoing percutaneous coronary revascularization with versus without stenting. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). 
  • Comparison of outcome after coronary angioplasty and coronary surgery for multivessel coronary artery disease in persons with diabetes. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparison of self-expanding and balloon-expandable stents for the reduction of restenosis. 
  • Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). 
  • Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). 
  • Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplasty. 
  • Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Complete resolution of systemic venous baffle obstruction and baffle leak using the Gore Excluder covered stent in two patients with transposition of the great arteries and prior Mustard procedure. 
  • Computer-assisted quantification of myocardial reperfusion after primary percutaneous coronary intervention predicts functional and contrast-enhanced cardiovascular magnetic resonance outcomes in patients with ST-segment elevation myocardial infarction. 
  • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. 
  • Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. 
  • Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). 
  • Contemporary pharmacological reperfusion in ST elevation myocardial infarction. 
  • Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. 
  • Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. 
  • Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Coronary Circulatory Indexes Before and After Percutaneous Coronary Intervention in a Porcine Tandem Stenoses Model. 
  • Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate. 
  • Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. 
  • Coronary artery angioplasty with a helical autoperfusion balloon catheter. 
  • Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. 
  • Coronary artery stents. American College of Cardiology. 
  • Coronary cyclic flow variations following primary angioplasty is associated with poor short-term prognosis. 
  • Coronary intervention and glycoprotein IIb/IIIa integrin blockade. 
  • Coronary intervention for persistent occlusion after myocardial infarction. 
  • Coronary interventions "to go": Is faster better? 
  • Coronary steal from a left internal mammary artery coronary bypass graft by a left upper extremity arteriovenous hemodialysis fistula. 
  • Coronary transluminal extraction-endarterectomy. 
  • Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. 
  • Correlations between preprocedure mood and clinical outcome in patients undergoing coronary angioplasty. 
  • Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). 
  • Costs of interventional cardiac procedures. 
  • Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). 
  • Creation of pseudo narrowing during coronary angioplasty. 
  • Creation of state-level Medicare database for healthcare evaluation applications. 
  • Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Current options in oral antiplatelet strategies during percutaneous coronary interventions. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current status of biodegradable stents. 
  • Cyclic coronary flow: defining preinfarction angina at the crossroads of unstable angina and myocardial infarction. 
  • Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. 
  • Decision models for assessing the cost effectiveness of drug-eluting stents. 
  • Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know? 
  • Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. 
  • Delayed percutaneous transluminal coronary angioplasty after acute myocardial infarction. 
  • Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway? 
  • Deployment of a previously embolized, unexpanded, and disarticulated Palmaz-Schatz stent. 
  • Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents. 
  • Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. 
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. 
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. 
  • Determining the cost economic "tipping point" for the addition of a regional percutaneous coronary intervention facility. 
  • Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications. 
  • Development of systems of care for ST-elevation myocardial infarction patients: the primary percutaneous coronary intervention (ST-elevation myocardial infarction-receiving) hospital perspective. 
  • Device implementation, validation, and application assessment of two continuous 12-lead ECG monitors during percutaneous transluminal coronary angioplasty: description of the validation method and implications for clinical trials. 
  • Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. 
  • Diagnosing coronary arterial stent thrombosis and arterial closure. 
  • Diagnosis and management of renovascular hypertension. 
  • Diagnosis and treatment of acute coronary ischemic syndromes: a update for 1995. 
  • Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. 
  • Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention. 
  • Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial. 
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. 
  • Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. 
  • Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
  • Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. 
  • Door-to-balloon time and mortality among patients undergoing primary PCI. 
  • Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the national cardiovascular data registry. 
  • Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. 
  • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. 
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 
  • Downstream testing and subsequent procedures after coronary computed tomographic angiography following coronary stenting in patients ≥65 years of age. 
  • Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. 
  • Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. 
  • Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. 
  • Drug-eluting stents in acute myocardial infarction: is science catching up with practice? 
  • Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. 
  • Drugs for percutaneous coronary interventions. 
  • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 
  • Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty. 
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. 
  • Early intervention: which patients and how early? 
  • Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. 
  • Early sustained ventricular arrhythmias complicating acute myocardial infarction. 
  • Early versus delayed invasive intervention in acute coronary syndromes. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic effects of extended clopidogrel therapy--a word of caution. 
  • Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. 
  • Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. 
  • Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. 
  • Economic impact of drug-eluting stents on hospital systems: a disease-state model. 
  • Economic impact of new interventional therapies: are we asking the right questions? 
  • Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. 
  • Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. 
  • Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). 
  • Effect of cardiac rehabilitation on functional outcomes after coronary revascularization. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 
  • Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. 
  • Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. 
  • Effect of gender on angioplasty outcome: are we closer to the answer? 
  • Effect of gender on the outcomes of contemporary percutaneous coronary intervention. 
  • Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. 
  • Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. 
  • Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study. 
  • Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. 
  • Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. 
  • Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. 
  • Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease. A prospective comparison study. 
  • Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. 
  • Effects of hemoperfusion during percutaneous transluminal coronary angioplasty on left ventricular function. 
  • Effects of local heparin administration on coronary thrombin activity during percutaneous transluminal coronary angioplasty. 
  • Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. 
  • Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. 
  • Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. 
  • Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). 
  • Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 
  • Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of nonocclusive etiologies. 
  • Electrocardiographic monitoring and coronary occlusion. Fingerprint pattern analysis in dimensions of space, time, and mind. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Emory Angioplasty Versus Surgery Trial (EAST): design, recruitment, and baseline description of patients. 
  • Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). 
  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 
  • Eptifibatide in percutaneous coronary intervention. A review. 
  • Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. 
  • Evaluating the exposure and disease relationship with adjustment for different types of exposure misclassification: a regression approach. 
  • Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 
  • Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. 
  • Evolving revascularization approaches for myocardial ischemia. 
  • Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. 
  • Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience. 
  • Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. 
  • Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. 
  • Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. 
  • Extensive thrombus prior to elective percutaneous coronary intervention. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 
  • Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove! 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitated versus primary PCI for acute myocardial infarction. 
  • Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. 
  • Feasibility and applicability of computer-assisted myocardial blush quantification after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). 
  • Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolysis or primary PCI in myocardial infarction. 
  • Finite-element analysis of balloon angioplasty. 
  • First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. 
  • Fixing the heart: must the brain pay the price? 
  • For how long should treatment with clopidogrel be continued after coronary stent implantation? 
  • Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. 
  • Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. 
  • Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • From theory to practice: implementation of pre-hospital electrocardiogram transmission in ST-elevation myocardial infarction - a multicenter experience. 
  • GP IIb/IIIa blockade in elective percutaneous coronary intervention. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Gender differences in the treatment of non-ST-segment elevation myocardial infarction. 
  • Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. 
  • Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. 
  • Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. 
  • Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. 
  • Grade 3 ischemia on the admission electrocardiogram predicts rapid progression of necrosis over time and less myocardial salvage by primary angioplasty. 
  • Ground emergency medical services requests for helicopter transfer of ST-segment elevation myocardial infarction patients decrease medical contact to balloon times in rural and suburban settings. 
  • Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. 
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 
  • Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. 
  • Have we made progress in reducing time to reperfusion in the management of acute myocardial infarction? A last decade overview. The potential key role of wireless electrocardiographic transmission. 
  • Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. 
  • Hemodynamic Parameters and Early Intimal Thickening in Branching Blood Vessels. 
  • High risk percutaneous coronary intervention and intra-aortic balloon pumps: when is the safety net needed? 
  • High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. 
  • Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). 
  • Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry. 
  • Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. 
  • Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. 
  • Hospital percutaneous coronary intervention volume and outcome: does it matter? 
  • Hybrid cutting balloon dilatation for treatment of cor triatriatum sinister in a cat. 
  • Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. 
  • Identification of patients with coronary disease at high risk for loss of employment. A prospective validation study. 
  • Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. 
  • Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. 
  • Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. 
  • Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. 
  • Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). 
  • Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). 
  • Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. 
  • Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. 
  • Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. 
  • Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. 
  • Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. 
  • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. 
  • Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Impact of time of presentation on the care and outcomes of acute myocardial infarction. 
  • Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). 
  • Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. 
  • Implications of cost in treatment selection for patients with coronary heart disease. 
  • Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. 
  • In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. 
  • In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. 
  • Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. 
  • Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. 
  • Incidence and predictors of stroke associated with percutaneous coronary intervention. 
  • Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. 
  • Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. 
  • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? 
  • Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study. 
  • Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors. 
  • Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. 
  • Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease. 
  • Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Inhibition of Factor Xa : a potential target for the development of new anticoagulants. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. 
  • Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? 
  • Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. 
  • Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot. 
  • Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). 
  • Interchangeability of activated clotting time values across different point-of-care systems. 
  • Interinstitutional variation in the use of abciximab for percutaneous coronary intervention. 
  • Internal mammary artery graft angioplasty: acute and long-term outcome. 
  • International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. 
  • Interpreting the music of drug-eluting stents: halcyon song or albatross dirge? 
  • Intervening on small infarct-related arteries: what does the future hold? 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Intracoronary brachytherapy: time to sell short? 
  • Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. 
  • Intracoronary ultrasound evaluation of interventional technologies. 
  • Intracoronary ultrasound predictors of adverse outcomes after coronary artery interventions. 
  • Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. 
  • Intravascular ultrasound in the management of acute coronary artery dissection: a case report. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. 
  • Is more better? 
  • Is thrombogenesis related to residual platelet function in ischaemic heart disease? 
  • Ischemic burden, treatment allocation, and outcomes in stable coronary artery disease. 
  • Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. 
  • Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire. 
  • Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. 
  • Late adverse events after drug-eluting stent implantation. 
  • Late outcomes after intervention of vein grafts in diabetics with abciximab use. 
  • Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). 
  • Left ventricular support systems for high-risk percutaneous coronary interventions: how can we improve outcomes for rare procedures? 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). 
  • Local delivery of heparin post-PTCA: a multicenter randomized pilot study. 
  • Localized delivery of nitric oxide from hydrogels inhibits neointima formation in a rat carotid balloon injury model. 
  • Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). 
  • Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Long-term clinical outcomes following coronary stenting. 
  • Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. 
  • Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. 
  • Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. 
  • Long-term outcomes of coronary-artery bypass grafting versus stent implantation. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry. 
  • Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. 
  • Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. 
  • Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). 
  • Major bleeding: management and risk reduction in acute coronary syndromes. 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Management of coronary artery disease in end-stage renal disease. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. 
  • Mayo Clinic Risk Score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). 
  • Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. 
  • Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. 
  • Medical economics and the assessment of value in cardiovascular medicine: Part II. 
  • Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. 
  • Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. 
  • Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. 
  • Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. 
  • Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? 
  • Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. 
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 
  • Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Mortality, kidney disease and cardiac procedures following acute coronary syndrome. 
  • Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction. 
  • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. 
  • Multicenter experience in revascularization of very elderly patients. 
  • Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. 
  • Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 
  • Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry. 
  • Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. 
  • Myocardial perfusion and ventricular function measurements during total coronary artery occlusion in humans. A comparison with rest and exercise radionuclide studies. 
  • Myocardial salvage after failed coronary angioplasty. 
  • Myonecrosis after revascularization procedures. 
  • Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • New concept in coronary angioplasty: dilatation with a helical balloon that allows simultaneous autoperfusion. 
  • New interventional technology for the management of multivessel coronary artery disease. 
  • Next-generation antithrombin therapies. 
  • Next-generation drug-eluting stents: a spirited step forward or more of the same. 
  • Nitric oxide-generating hydrogels inhibit neointima formation. 
  • No jacket required. 
  • Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. 
  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Nonsystem reasons for delay in door-to-balloon time and associated in-hospital mortality: a report from the National Cardiovascular Data Registry. 
  • Novel constructs for thrombin inhibition. 
  • Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. 
  • One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. 
  • One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). 
  • Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. 
  • Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). 
  • Optimising outcomes: socioeconomic perspective. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction. 
  • Outcome after prolonged balloon inflations of greater than 20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. 
  • Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. 
  • Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes after percutaneous coronary artery revascularization procedures for cardiac allograft vasculopathy in pediatric heart transplant recipients: A multi-institutional study. 
  • Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. 
  • Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). 
  • Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital. 
  • Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents. 
  • Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). 
  • Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. 
  • Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). 
  • Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. 
  • PCI at non-PCI centres: immediate or rescue? 
  • Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. 
  • Patient selection for diagnostic coronary angiography and hospital-level percutaneous coronary intervention appropriateness: insights from the National Cardiovascular Data Registry. 
  • Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). 
  • Patterns of cardiac stress testing after revascularization in community practice. 
  • Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). 
  • Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. 
  • Percutaneous coronary intervention and drug-eluting stent use among patients ≥85 years of age in the United States. 
  • Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. 
  • Percutaneous coronary intervention in the elderly. 
  • Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? 
  • Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). 
  • Percutaneous coronary intervention versus coronary artery bypass grafting for diabetics with multivessel coronary artery disease: the Korean Multicenter Revascularization Registry (KORR). 
  • Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. 
  • Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. 
  • Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Percutaneous coronary revascularisation: is it ever worth what it costs? 
  • Percutaneous coronary revascularization in diabetic patients with multivessel coronary artery disease: importance and feasibility. 
  • Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. 
  • Percutaneous interventions in high-risk patients following Mustard repair of transposition of the great arteries. 
  • Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent. 
  • Percutaneous revascularization of chronic coronary occlusions: an overview. 
  • Percutaneous transluminal coronary angioplasty as a first revascularization procedure in single-, double- and triple-vessel coronary artery disease. 
  • Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris. 
  • Percutaneous transluminal coronary angioplasty in women compared with men. 
  • Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot study. 
  • Performance of a body surface mapping system using emergency physician real-time interpretation. 
  • Performance of an automated real-time ST-segment analysis program to detect coronary occlusion and reperfusion. 
  • Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention--From the PROTECT II randomized trial. 
  • Perfusion balloon angioplasty in patients with complex coronary lesion morphology. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. 
  • Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). 
  • Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pexelizumab and the APEX AMI trial. 
  • Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. 
  • Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. 
  • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. 
  • Pharmacogenetic guidance for antiplatelet treatment. 
  • Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacotherapy: Intracoronary streptokinase in acute myocardial infarction. 
  • Physical function and independence 1 year after myocardial infarction: observations from the Translational Research Investigating Underlying disparities in recovery from acute Myocardial infarction: Patients' Health status registry. 
  • Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. 
  • Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window. 
  • Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. 
  • Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. 
  • Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. 
  • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Pooled RCTs: CABG reduces mortality more than PCI with DES in nondiabetic patients with multivessel CAD. 
  • Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? 
  • Post-pericardiotomy syndrome after percutaneous balloon pericardiotomy. 
  • Post-procedure heparin: boon or burden? 
  • Postcoronary thrombolysis management. 
  • Postinfarction ventricular septal defects: surgical or percutaneous closure-between a rock and a hard place. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. 
  • Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. 
  • Prediction is very hard, especially about the future: comment on "factors associated with 30-day readmission rates after percutaneous coronary intervention". 
  • Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. 
  • Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. 
  • Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. 
  • Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. 
  • Predictors of 30-day cardiovascular events in patients with prior percutaneous coronary intervention or coronary artery bypass grafting. 
  • Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). 
  • Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry. 
  • Predictors of outcome of reperfusion therapy. 
  • Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization. 
  • Preferences for cardiac tests and procedures may partially explain sex but not race disparities. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Preliminary observations using optical coherence tomography to assess neointimal coverage of a metal stent in a porcine model. 
  • Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. 
  • Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 
  • Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. 
  • Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. 
  • Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. 
  • Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Primary angioplasty or thrombolysis for acute myocardial infarction? 
  • Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. 
  • Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). 
  • Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. 
  • Primary renal artery stenting: characteristics and outcomes after 363 procedures. 
  • Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock. The left main shock syndrome. 
  • Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. 
  • Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. 
  • Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. 
  • Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. 
  • Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). 
  • Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. 
  • Prognostic value of thallium-201 single-photon emission computed tomography for patients with multivessel coronary artery disease after revascularization (the Emory Angioplasty versus Surgery Trial [EAST]). 
  • Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans. 
  • Prospective evaluation of where reperfusion ventricular arrhythmia "bursts" fit into optimal reperfusion in STEMI. 
  • Provisional stenting versus routine stenting: is it worth the price? 
  • Provisional vs. complex stenting strategy for coronary bifurcation lesions: meta-analysis of randomized trials. 
  • Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. 
  • Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. 
  • Quality of life after coronary revascularization in the United States and Canada. 
  • Quality of life after late invasive therapy for occluded arteries. 
  • Quantification of ST-segment changes during coronary angioplasty in patients with left bundle branch block. 
  • Quantification of myocardial hypoperfusion with 99m Tc-sestamibi in patients undergoing prolonged coronary artery balloon occlusion. 
  • Quantitative and qualitative ST segment monitoring during and after percutaneous transluminal coronary angioplasty. 
  • ROC methodology within a monitoring framework. 
  • Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). 
  • Racial variation in the use of coronary-revascularization procedures. 
  • Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? 
  • Radiation effects in fluoroscopically guided cardiac interventions--keeping them under control. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. 
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. 
  • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. 
  • Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts. 
  • Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site. 
  • Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. 
  • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 
  • Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. 
  • Readministration of abciximab: interim report of the ReoPro readministration registry. 
  • Rear-view mirror observations on bleeding in acute coronary syndromes. 
  • Rebuttal: the CTO "no-controversy" controversy: should the field of CTO-PCI be allowed to expand? 
  • Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. 
  • Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. 
  • Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. 
  • Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. 
  • Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. 
  • Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). 
  • Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. 
  • Regionalization of percutaneous transluminal coronary angioplasty and implications for patient travel distance. 
  • Relation between activated clotting time during angioplasty and abrupt closure. 
  • Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single-vessel coronary artery disease. The Veterans Affairs ACME Investigators. 
  • Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. 
  • Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). 
  • Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. 
  • Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. 
  • Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. 
  • Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. 
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. 
  • Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. 
  • Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. 
  • Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. 
  • Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. 
  • Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. 
  • Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. 
  • Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. 
  • Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). 
  • Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. 
  • Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. 
  • Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. 
  • Reperfusion and revascularization strategies for coronary artery disease in women. 
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. 
  • Reperfusion for acute myocardial infarction: is the future in plastics? 
  • Reperfusion in waiting: what queue should we join? 
  • Reperfusion is delayed beyond guideline recommendations in patients requiring interhospital helicopter transfer for treatment of ST-segment elevation myocardial infarction. 
  • Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. 
  • Reperfusion paradox in ST-segment elevation myocardial infarction. 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. 
  • Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. 
  • Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. 
  • Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: insights from the National Cardiovascular Data Registry (NCDR). 
  • Reperfusion ventricular arrhythmia 'bursts' in TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction: a more precise definition of reperfusion arrhythmias. 
  • Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. 
  • Reply: High-Risk Percutaneous Coronary Interventions: First, Do No Harm. 
  • Resource use and cost of initial coronary revascularization. Coronary angioplasty versus coronary bypass surgery. 
  • Resource use trajectories for aged medicare beneficiaries with complex coronary conditions. 
  • Response variability and the role of platelet function testing. 
  • Restenosis after coronary angioplasty: an overview. 
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). 
  • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. 
  • Results of high dose intravenous urokinase for acute myocardial infarction. 
  • Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. 
  • Revascularization for heart failure. 
  • Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Risk of distal embolization and infarction with transluminal extraction atherectomy in saphenous vein grafts and native coronary arteries. NACI Investigators. New Approaches to Coronary Interventions. 
  • Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. 
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Risk-benefit trade-offs in revascularisation choices. 
  • Role of nuclear imaging after coronary revascularization. 
  • Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women. 
  • Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 
  • ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • ST-segment-elevation myocardial infarction treatment and the seductive lure of observational analyses. 
  • SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Safety of abciximab administration during PCI of patients with previous stroke. 
  • Same day discharge following transradial PCI in India: Creating value for patients and providers. 
  • Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? 
  • Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. 
  • Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. 
  • Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes. 
  • Serum cholesterol in patients undergoing cardiac catheterization for suspected coronary artery disease: diagnostic and prognostic implications. 
  • Severe coronary artery disease: is there a place for percutaneous coronary intervention? 
  • Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. 
  • Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery. 
  • Should reperfusion strategies in myocardial infarction be modified for the very elderly? 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Simultaneous comparison of 3 derived 12-lead electrocardiograms with standard electrocardiogram at rest and during percutaneous coronary occlusion. 
  • Simultaneous restenosis of Taxus and Cypher drug-eluting stents. 
  • Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. 
  • Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. 
  • Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. 
  • Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Specificity of procedure volume and in-hospital mortality association. 
  • Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. 
  • Steroids for restenosis: strike three! 
  • Stress imaging use and repeat revascularization among medicare patients with high-risk coronary artery disease. 
  • Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. 
  • Successful percutaneous coronary intervention with stent implantation in anomalous right coronary arteries arising from the left sinus of valsalva: a report of two cases. 
  • Sudden cardiac death due to large coronary aneurysm successfully treated with a covered stent and ChromaFlo guidance. 
  • Summary of evidence regarding hospital strategies to reduce door-to-balloon times for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. 
  • Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation. 
  • Survival in renal vascular disease. 
  • Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. 
  • TIMI IIB follow-up. Lessons for clinicians and investigators. 
  • Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit. 
  • Tc-99m sestamibi cardiac SPECT imaging during coronary artery occlusion in humans: comparison with dipyridamole stress studies. 
  • Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up. 
  • Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. 
  • Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. 
  • Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. 
  • Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. 
  • Temporal trends in target vessel revascularization in clinical practice: long-term outcomes following coronary stenting from the Duke Database for Cardiovascular Disease. 
  • The CHD challenge: comparing four cost-effectiveness models. 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The New York State Primary Angioplasty Registry and procedural volume. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The benefit of abciximab in percutaneous coronary revascularization is not device-specific. 
  • The bifurcation stent. 
  • The challenge of defining bleeding among patients with acute coronary syndromes. 
  • The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry. 
  • The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 
  • The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. 
  • The contrast media iohexol causes vasoconstriction of the proximal left anterior descending coronary artery: implications for appropriate stent sizing. 
  • The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model. 
  • The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of managed care penetration on the treatment of AMI in the fee-for-service Medicare population. 
  • The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. 
  • The emerging role of percutaneous intervention in adults with congenital heart disease. 
  • The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. 
  • The everlasting effect of primary percutaneous coronary intervention--even after transport? 
  • The health care burden of unstable angina. 
  • The impact of autoperfusion on quantitative electrocardiographic parameters of ischemia severity, extent, and "burden" during salvage of elective coronary angioplasty. 
  • The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE Initiative. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The impact of statistical adjustment on economic profiles of interventional cardiologists. 
  • The inclusion of patient testimonials in decision aids: effects on treatment choices. 
  • The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. 
  • The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. 
  • The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. 
  • The natural history of single-vessel chronic coronary occlusion: a 25-year experience. 
  • The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: a preliminary report of a new device for the noninvasive detection of successful reperfusion or silent coronary reocclusion. 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The process of bringing new drug-eluting stents to market will they see the light of day? 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of angioplasty after successful thrombolysis for acute myocardial infarction. 
  • The role of fibrinolytics in the prehospital treatment of ST-elevation myocardial infarction (STEMI). 
  • The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. 
  • The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. 
  • The role of reperfusion therapy in paced patients with acute myocardial infarction. 
  • The role of risk models in upholding standards for percutaneous coronary interventions. 
  • The role of the perfusion balloon catheter after an initially unsuccessful coronary intervention. 
  • The search for myocardial protection: is there still hope? 
  • The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. 
  • The truth and consequences of the COURAGE trial. 
  • The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. 
  • The use of intraaortic balloon counterpulsation in acute myocardial infarction and high risk coronary angioplasty. 
  • The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • The use of the Tracker catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Thermal-perfusion balloon coronary angioplasty: in vivo evaluation. 
  • Three-year outcomes of multivessel revascularization in very elderly acute coronary syndrome patients. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. 
  • Time to treatment as a quality metric for acute STEMI care. 
  • Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • To stent or not to stent--that is the question. 
  • To transfer or not to transfer: acute myocardial infarction reperfusion. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Transient electrocardiographic changes of elective coronary angioplasty compared with evolutionary changes of subsequent acute myocardial infarction observed with continuous three-lead monitoring. 
  • Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? 
  • Transmyocardial laser revascularization for inoperable coronary artery disease. 
  • Transradial PCI in women: problem solved or clinical equipoise? 
  • Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. 
  • Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). 
  • Treatment of acute myocardial infarction. 
  • Treatment of long coronary artery narrowings with long angioplasty balloon catheters. 
  • Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. 
  • Treatment selection for coronary artery disease: The collision of a belief system with evidence. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. 
  • Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. 
  • Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. 
  • Trends in emergency coronary artery bypass grafting after percutaneous coronary intervention, 1994-2003. 
  • Trends in operator and hospital procedure volume and outcomes for percutaneous transluminal coronary angioplasty, 1996 to 2001. 
  • Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. 
  • Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. 
  • Trends in the use of diagnostic coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft surgery across North Carolina. 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Troponin criteria for myocardial infarction after percutaneous coronary intervention. 
  • Twelve-lead electrocardiogram recording during percutaneous transluminal coronary angioplasty. Analysis of reciprocal changes. 
  • Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. 
  • Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors. 
  • Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. 
  • Unrecognized left main coronary artery disease in patients undergoing interventional procedures. 
  • Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. 
  • Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. 
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. 
  • Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. 
  • Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. 
  • Use of the perfusion balloon as a primary dilation device. 
  • Usefulness of dobutamine echocardiography for detecting restenosis after percutaneous transluminal coronary angioplasty. 
  • Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. 
  • Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. 
  • Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. 
  • Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Utility of observation units for young emergency department chest pain patients. 
  • Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Variations in coronary procedure utilization depending on body mass index. 
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Volume of coronary angioplasty procedures and mortality rates. 
  • Volume-outcome relationship in acute myocardial infarction: the balloon and the needle. 
  • Volume-outcome relationships for percutaneous coronary interventions in the stent era. 
  • Vulnerable plaque intervention: State of the art. 
  • Walking pace is inversely associated with risk of death and cardiovascular disease: The Physicians' Health Study. 
  • What constitutes optimal surgical revascularization? Answers from the Bypass Angioplasty Revascularization Investigation (BARI). 
  • What do you need to know before performing a percutaneous coronary intervention? 
  • Which is the true channel? 
  • Who should have a routine early invasive approach after fibrinolytic therapy? 
  • Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. 
  • Willingness to participate in cardiac trials. 
  • [Laser coronary angioplasty. Critical analysis of the first patients]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine